Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748965 | 0.90 | PSEN1 (0.41) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19787521 | 0.87 | APP (0.54) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29801652 | 0.87 | APP (0.54) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19787528 | 0.82 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19787533 | 0.79 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19787598 | 0.77 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19787530 | 0.75 | PSEN1 (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22435549 | 0.73 | KDM4E (0.51) | YTHDC1 | |
| SCHEMBL30748721 | 0.73 | CCNE2 (0.43) | APP | |
| SCHEMBL22915357 | 0.73 | PSEN1 (0.60) | APPPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200291032-A1 | PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2019101984-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291032-A1 | PYRIMIDINE DERIVATIVES | TYMS, DPYD, TYMP | APP 3509/4885PSEN1 2977/4885PSEN2 2603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.